Expertise in
6
conditions

Anna L. Godfrey

Cambridge, ENG, GB 
Expertise in
6
conditions
Cambridge, ENG, GB 

Overview

Anna Godfrey practices practicing medicine in Cambridge, United Kingdom.

Ms. Godfrey is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Essential Thrombocythemia, Polycythemia Vera, and Philadelphia-Negative Chronic Myeloid Leukemia.

She is actively involved in clinical research, co-authoring 62 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Cambridge, ENG, United Kingdom
Other Locations
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

62 Total Publications

Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.
Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.
Journal: Cancer discovery
Published: February 26, 2026

Frequently Asked Questions about Anna L. Godfrey

Is Anna L. Godfrey a top-rated expert for Myeloproliferative Neoplasms (MPN)?

MediFind is an objective health platform that identifies experts based on real-world data. Anna L. Godfrey is classified as an Distinguished expert for Myeloproliferative Neoplasms (MPN), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anna L. Godfrey participate in research or clinical trials?

Yes. Anna L. Godfrey has published 62 articles and abstracts on conditions like Myeloproliferative Neoplasms (MPN). You can view a list of Anna L. Godfrey's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Godfrey's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile